

Schaffhausen, June 2, 2011

**Announcement according to Art. 9 and Art. 21 SESTO-FINMA  
Disclosure of shareholdings**

Pursuant to Art. 9 and Art. 21 SESTO-FINMA, The Bank of New York Mellon Corporation, New York, USA, has announced to BB Biotech AG, Schaffhausen, Switzerland, that its holding in registered shares BB Biotech AG (ISIN CH0038389992) increased to more than 5% of the proportion of voting rights as per May 27, 2011.

The Bank of New York Mellon Corporation, New York, USA, held 960 661 voting rights (5.27% of the proportion of voting rights) as per May 27, 2011, directly or indirectly by the companies listed below:

**Direct Holders:**

- Newton Investment Management AG Ltd., London, England
- BNY Mellon Service-Kapitalanlage-Gesellschaft mbH, Frankfurt, Germany

**Indirect Holders:**

- MBC Investments Corporation, Greenville, Delaware, USA
- Neptune LLC, Pittsburgh, Pennsylvania, USA
- Mellon International Holdings S.a.r.l., Luxembourg
- BNY Mellon International Asset Management Group Limited, London, England
- Newton Management Limited, London, England
- The Bank of New York Mellon, New York, USA
- BNY International Financing Corporation, New York, USA
- The Bank of New York Mellon SA/NV, Brussels, Belgium
- BNY Mellon Asset Servicing GmbH, Frankfurt, Germany

**For further information, please contact:**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland  
Thomas Egger, Tel. +41 44 267 67 00, [teg@bellevue.ch](mailto:teg@bellevue.ch)  
[www.bbbiotech.com](http://www.bbbiotech.com)

**Company profile**

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with CHF 1.2 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.